• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Study: Active surveillance uptake remains low


The overall use of active surveillance in men with low-risk prostate cancer is 14.2%, according to an examination of the National Cancer Data Base.

Boston-The overall use of active surveillance (AS) in men with low-risk prostate cancer is 14.2%, according to an examination of the National Cancer Data Base.

In addition, variation in the use of AS is significant across facilities, reported Björn Löppenberg, MD, at the AUA annual meeting in Boston.

Dr. Loppenberg“Given current concerns for overdiagnosis and overtreatment of indolent prostate cancer, low rates and inconsistent use of active surveillance are alarming,” said Dr. Löppenberg, fellow in the division of urologic surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Boston.

Recent reports on the utilization of AS in the U.S. have shown encouraging results. The Michigan Urological Surgery Improvement Collaborative (MUSIC) of 17 Michigan-based practices reported that 48% of eligible patients received AS. Other collectives report utilization rates of AS in the range of 40%.

Also see: Top 9 peer-reviewed prostate cancer papers of 2017

“However, these reports are limited to certain geographical regions or certain patient collectives,” he said.

The Brigham and Women's Hospital group conducted a retrospective cohort study of 40,215 men with low-risk prostate cancer within the National Cancer Data Base, diagnosed in 2012 and 2013. Low risk was defined as cT1-cT2 disease with a serum PSA level <10.0 ng/mL and a Gleason score ≤6.

“Additionally, we wanted to assess the variation in care; therefore, we used a mixed-effects model to assess which factors contribute to variation,” said Dr. Löppenberg, who worked on the study with Quoc-Dien Trinh, MD, and colleagues.

Some 1,172 facilities were included in the analysis. Overall, 14.2% of eligible men received AS. The unadjusted rate in treatment variation ranged from 0 to 62% in facilities treating more than 75 patients within the study period.

Next: Facility volume, type linked with AS


Facility volume, type linked with AS

Factors associated with receipt of AS were facility volume and facility type. The odds ratio of receipt of AS was 3.5 (95% CI: 1.84-6.68; p<.001) in facilities with the highest volume compared with lowest volume. The highest likelihood of receipt of AS was in community cancer programs and academic institutions. Relative to patients treated at comprehensive community cancer centers, patients treated at community cancer programs had an OR of 2.74 (95% CI: 1.94-3.88; p<.001) and those treated at academic institutions had an OR of 2.50 (95% CI: 1.77-3.54; p<.001).

“There are some high-volume facilities that almost never treat patient with AS,” Dr. Löppenberg said.

Adjusted for all factors, the mean probability of receiving AS was 0.033 (95% CI: 0.023-0.256).

Read: Genomic testing linked to higher surveillance uptake

The overall model explained 40% of the variation in receipt of AS. Of the unexplained variation, 35% could be attributed to a single facility, he said.

“Policies to achieve more consistent and higher rates of AS, when appropriate, should be a priority of professional societies and patient advocacy groups,” Dr. Löppenberg said.

The National Cancer Data Base captures about 70% of all newly diagnosed prostate cancer in the United States, he explained.

“The NCDB estimates that approximately 50% of all newly diagnosed prostate cancers are within their database,” he said. “So we think that quite a large proportion of these patients do not receive AS.”

More from Urology Times:

CCP score further risk stratifies surveillance candidates

Current prostate Ca guidelines miss germline variants

RT-ADT combo may boost pN1 prostate cancer survival

Subscribe to Urology Times to get monthly news from the leading news source for urologists.

Related Videos
Samuel L. Washington III, MD, MAS, answers a question during a Zoom video interview
Conceptual image for prostate cancer treatment | © Dr_Microbe - stock.adobe.com
Female doctor talking with male patient | Image Credit: © Prostock-studio - stock.adobe.com
Daniel A. Triner, MD, PhD, answers a question during a Zoom video interview
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr_Microbe - stock.adobe.com
Doctor consulting with patient | Image Credit: © Khunatorn - stock.adobe.com
Scott Morgan, MD, MSc, FRCPC, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.